Cargando…

Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer

BACKGROUND: Immune checkpoint blockade therapy has clearly shown clinical activity in patients with triple-negative breast cancer, but less than half of the patients benefit from the treatments. While a number of ongoing clinical trials are investigating different combinations of checkpoint inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Hanwen, Ma, Huilin, Sové, Richard J, Emens, Leisha A, Popel, Aleksander S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883871/ https://www.ncbi.nlm.nih.gov/pubmed/33579739 http://dx.doi.org/10.1136/jitc-2020-002100

Ejemplares similares

Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer
por: Wang, Hanwen, et al.
Publicado: (2022)

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
por: Emens, Leisha A, et al.
Publicado: (2021)

Correction: Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Publicado: (2021)

PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer
por: Rugo, Hope S, et al.
Publicado: (2021)

A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 inhibition
por: Arulraj, Theinmozhi, et al.
Publicado: (2023)

QSP‐IO: A Quantitative Systems Pharmacology Toolbox for Mechanistic Multiscale Modeling for Immuno‐Oncology Applications
por: Sové, Richard J., et al.
Publicado: (2020)

ESMO 2018 presidential symposium—IMpassion130: atezolizumab+nab-paclitaxel in triple-negative breast cancer
por: Schmid, Peter
Publicado: (2018)

Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety
por: Sharmni Vishnu, K., et al.
Publicado: (2022)

A Quantitative Systems Pharmacology Model of T Cell Engager Applied to Solid Tumor
por: Ma, Huilin, et al.
Publicado: (2020)

LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
por: Emens, L.A., et al.
Publicado: (2020)

Targeting ANXA1 abrogates Treg-mediated immune suppression in triple-negative breast cancer
por: Bai, Fang, et al.
Publicado: (2020)

Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer
por: Cao, Xu, et al.
Publicado: (2021)

ELK3 modulates the antitumor efficacy of natural killer cells against triple negative breast cancer by regulating mitochondrial dynamics
por: Park, Joo Dong, et al.
Publicado: (2022)

GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer
por: Wei, Jin-Li, et al.
Publicado: (2021)

Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
por: Liu, Huicheng, et al.
Publicado: (2021)

Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model
por: Sové, Richard J, et al.
Publicado: (2022)

Simulations of tumor growth and response to immunotherapy by coupling a spatial agent-based model with a whole-patient quantitative systems pharmacology model
por: Ruiz-Martinez, Alvaro, et al.
Publicado: (2022)

circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622/CMTM6 axis to promote triple-negative breast cancer and immune escape
por: Dong, Li-Feng, et al.
Publicado: (2023)

Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors
por: Wang, Hanwen, et al.
Publicado: (2020)

Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
por: Fabi, Alessandra, et al.
Publicado: (2023)

Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab
por: Molinero, Luciana, et al.
Publicado: (2019)

Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model
por: Ma, Huilin, et al.
Publicado: (2020)

Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic Biomarkers
por: Mi, Haoyang, et al.
Publicado: (2022)

Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
por: Fabi, Alessandra, et al.
Publicado: (2023)

Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies
por: De Giglio, Andrea, et al.
Publicado: (2019)

Integrating single cell sequencing with a spatial quantitative systems pharmacology model spQSP for personalized prediction of triple-negative breast cancer immunotherapy response
por: Zhang, Shuming, et al.
Publicado: (2021)

Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study
por: Arpino, Grazia, et al.
Publicado: (2015)

Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma
por: Shui, Lin, et al.
Publicado: (2020)

Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer
por: Mi, Haoyang, et al.
Publicado: (2020)

Tumor Lysis Syndrome After a Single Dose of Atezolizumab with Nab-Paclitaxel: A Case Report and Review of Literature
por: Carrier, Xavier, et al.
Publicado: (2020)

Atezolizumab in combination with carboplatin plus nab‐paclitaxel for managing combined large‐cell neuroendocrine carcinoma: A case report
por: Tsutsumi, Rei, et al.
Publicado: (2022)

Safety and Efficacy of Camrelizumab in Combination With Nab-Paclitaxel Plus S-1 for the Treatment of Gastric Cancer With Serosal Invasion
por: Lin, Ju-Li, et al.
Publicado: (2022)

Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy
por: Wang, Yan, et al.
Publicado: (2020)

MCT4 blockade increases the efficacy of immune checkpoint blockade
por: Babl, Nathalie, et al.
Publicado: (2023)

Atezolizumab plus carboplatin and nab‐paclitaxel versus carboplatin and nab‐paclitaxel as treatments for Chinese, treatment‐naïve, stage IV, non‐squamous, non‐small‐cell lung cancer patients: A retrospective analysis
por: Chen, Yingkai, et al.
Publicado: (2022)

CXCR6 is required for antitumor efficacy of intratumoral CD8(+) T cell
por: Wang, Binglin, et al.
Publicado: (2021)

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
por: Halle, Briana Rose, et al.
Publicado: (2021)

Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer
por: Li, Yi, et al.
Publicado: (2019)

Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors
por: Kalinovsky, Daniel V, et al.
Publicado: (2022)

Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer
por: Boelaars, Kelly, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_r08mdq0imb1ugl139j0f6ouc32